Table 3.

Summary of combination strategies of bispecific antibodies in clinical trials.

Strategy 1: Combination with other anti-myeloma agents
Rationale: Potential synergistic effect, reduced tumor burden.
Trial No.	Agents
NCT03287908 (Phase 1)	Pavurutamab (AMG 701) monotherapy Pavurutamab + pomalidomide Pavurutamab + pomalidomide + dexamethasone
NCT04108195 TriMM-2 (Phase 1)	Talquetamab + daratumumab Teclistamab + daratumumab Then ± pomalidomide
NCT05090566 MagnetisMM-4 (Phase 2)	Sub-study B Elranatamab + lenalidomide + dexamethasone
NCT05020236 MagnetisMM-5 (Phase 3)	Elranatamab vs daratumumab+ pomalidomide+ dexamethasone Elranatamab + daratumumab vs daratumumab+ pomalidomide+ dexamethasone
NCT05137054 (Phase 1)	Linvoseltamab (REGN5458) + daratumumab + dexamethasone Linvoseltamab + carfilzomib + dexamethasone Linvoseltamab + lenalidomide + dexamethasone Linvoseltamab + bortezomib + dexamethasone
Strategy 2: Combination of 2 bispecific molecules targeting various MM antigens
Rationale: To reduce the risk of antigen loss related disease relapse.
NCT04586426 (Phase 1)	Part 2: Dose expansion cohort Talquetamab + teclistamab Talquetamab + teclistamab + daratumumab
Strategy 3: Combined agent which enhances expression of target antigen
Rationale: Enhanced antigen expression increased anti-MM activity of bispecific molecules
NCT04722146 (Phase 1)	Talquetamab + nirogacestat
NCT05090566 MagnetisMM-4 (Phase 2)	Sub-study A Elranatamab + nirogacestat